Literature DB >> 19327377

Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins.

Katerina Capková1, Nicholas T Salzameda, Kim D Janda.   

Abstract

Botulinum neurotoxins (BoNTs), proteins secreted by the bacteria genus Clostridium, represent a group of extremely lethal toxins and a potential bioterrorism threat. As the current therapeutic options are of a predominantly prophylactic nature and cannot be used en masse, new strategies and ultimately potential treatments are desperately needed to combat any widespread release of these neurotoxins. In these regards, our laboratory has been working on developing new alternatives to treat botulinum intoxication through the development of inhibitors of the light chain proteases, the etiological agent which causes BoNT intoxication. Such a strategy has required the construction of two high-throughput screens and small molecule non-peptidic libraries; excitingly, inhibitors of the BoNT/A protease have been uncovered and are being optimized via structure activity relationship studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327377      PMCID: PMC2730986          DOI: 10.1016/j.toxicon.2009.03.016

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  46 in total

1.  Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution.

Authors:  R B Sutton; D Fasshauer; R Jahn; A T Brunger
Journal:  Nature       Date:  1998-09-24       Impact factor: 49.962

2.  Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities.

Authors:  B Hallis; B A James; C C Shone
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

3.  Proteolysis of synthetic peptides by type A botulinum neurotoxin.

Authors:  J J Schmidt; K A Bostian
Journal:  J Protein Chem       Date:  1995-11

4.  Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin.

Authors:  J J Schmidt; K A Bostian
Journal:  J Protein Chem       Date:  1997-01

5.  Substrate recognition strategy for botulinum neurotoxin serotype A.

Authors:  Mark A Breidenbach; Axel T Brunger
Journal:  Nature       Date:  2004-12-12       Impact factor: 49.962

6.  Sequence homology and structural analysis of the clostridial neurotoxins.

Authors:  D B Lacy; R C Stevens
Journal:  J Mol Biol       Date:  1999-09-03       Impact factor: 5.469

7.  Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin.

Authors:  C C Shone; A K Roberts
Journal:  Eur J Biochem       Date:  1994-10-01

8.  Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity.

Authors:  M Adler; J D Nicholson; F Cornille; B E Hackley
Journal:  FEBS Lett       Date:  1998-06-16       Impact factor: 4.124

Review 9.  The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors.

Authors:  Jerry W Skiles; Nina C Gonnella; Arco Y Jeng
Journal:  Curr Med Chem       Date:  2004-11       Impact factor: 4.530

Review 10.  Mechanism of action of tetanus and botulinum neurotoxins.

Authors:  C Montecucco; G Schiavo
Journal:  Mol Microbiol       Date:  1994-07       Impact factor: 3.501

View more
  11 in total

1.  Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design.

Authors:  Petr Capek; Yan Zhang; Deborah J Barlow; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

2.  Pharmacophore Refinement Guides the Rational Design of Nanomolar-Range Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease.

Authors:  Jonathan E Nuss; Yuxiang Dong; Laura M Wanner; Gordon Ruthel; Peter Wipf; Rick Gussio; Jonathan L Vennerstrom; Sina Bavari; James C Burnett
Journal:  ACS Med Chem Lett       Date:  2010-10-14       Impact factor: 4.345

3.  Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity.

Authors:  Martha Hale; George Oyler; Subramanyam Swaminathan; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

4.  Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.

Authors:  Joseph S Zakhari; Isao Kinoyama; Mark S Hixon; Antonia Di Mola; Daniel Globisch; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2011-09-14       Impact factor: 3.641

5.  Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore.

Authors:  James C Burnett; Bing Li; Ramdas Pai; Steven C Cardinale; Michelle M Butler; Norton P Peet; Donald Moir; Sina Bavari; Terry Bowlin
Journal:  Open Access Bioinformatics       Date:  2010-04-01

6.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

7.  Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease.

Authors:  G Neil Stowe; Peter Silhár; Mark S Hixon; Nicholas R Silvaggi; Karen N Allen; Scott T Moe; Alan R Jacobson; Joseph T Barbieri; Kim D Janda
Journal:  Org Lett       Date:  2010-02-19       Impact factor: 6.005

8.  3-Hydroxy-1-alkyl-2-methylpyridine-4(1H)-thiones: Inhibition of the Pseudomonas aeruginosa Virulence Factor LasB.

Authors:  Amanda L Garner; Anjali K Struss; Jessica L Fullagar; Arpita Agrawal; Amira Y Moreno; Seth M Cohen; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2012-06-19       Impact factor: 4.345

9.  Discovery of Dipeptides as Potent Botulinum Neurotoxin A Light-Chain Inhibitors.

Authors:  Martin Amezcua; Ricardo S Cruz; Alex Ku; Wilfred Moran; Marcos E Ortega; Nicholas T Salzameda
Journal:  ACS Med Chem Lett       Date:  2021-01-27       Impact factor: 4.345

10.  Tyrosine phosphorylation of botulinum neurotoxin protease domains.

Authors:  Stephen Toth; Ernst E Brueggmann; George A Oyler; Leonard A Smith; Harry B Hines; S Ashraf Ahmed
Journal:  Front Pharmacol       Date:  2012-06-04       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.